Seqens
  • About Us
    • About Seqens
    • New England Locations
    • Client Testimonials
    • Affiliations
  • R&D and Analytics
    • Research Development
    • Preclinical/Kilo Scale
    • Reaction Technologies
    • Analytical and Quality Control
  • API Manufacturing
    • API Manufacturing at Seqens
    • Controlled Substance API manufacturing
    • Cryogenic API Manufacturing
    • API Phase I – III
    • Commercial API Production
    • Quality Assurance / Regulatory
    • cGMP Medical Grade Polymers
    • Advanced Materials
  • Products
  • News
  • Contact Us
    • Accelerate your API manufacturing project
    • Download Our Brochure
    • Confidential Disclosure Agreement
  • Careers
    • View all open positions
Select Page

How to Control Impurities during API drug manufacturing

by SEQENS North America | Feb 19, 2018 | API Manufacturing, Impurities, Video

Dr. Rajesh Shukla, Vice President Research and Development at Seqens Talks about Controlling Impurities during API drug manufacturing.

Related posts:

Four Keys to Optimizing Process Research
Do's and Don'ts of API Technology Transfer in Phases 1, 2 and 3 Clinical Trials
7 things to look for in a CMO’S CGMP Manufacturing Capabilities
Massachusetts Maintains Status as Leading Life Sciences Hub
How Sponsors and CDMOs are Preparing to Manufacture APIs for Complex Generic 3 Criteria for picking ...
  • Follow
  • Follow
  • Follow
© 2023 Seqens North America | 9 Opportunity Way | Newburyport, MA 01950 Tel: (978) 462-5555 | inquiries@seqens.com
Terms and Conditions | Contact Us